Chapter 61:The Net Tightens

The email was waiting in Leah's inbox when she sat down at her desk. It was from Priya Sharma, the senior archivist, and it was marked URGENT. "Catherine — per David's request, please report to Conference Room 34-B at 9:00 AM for a preliminary discussion regarding the NexGen clinical data discrepancy analysis. Sebastian Costa will be joining via video link. Please bring your working files and be prepared to present your findings to the group." Leah read the email twice. The details were routine — she had already submitted her analysis to David, and a follow-up meeting was expected. But two things were wrong. First: Sebastian Costa. He had never attended a working-level meeting on clinical data. His involvement meant the NexGen situation had escalated beyond the legal team — Sebastian was personally invested now, which meant the SEC investigation was creating pressure at the highest levels of Costa Holdings. Second: the timing. The meeting was in forty-five minutes. Leah had not been given advance notice. This was either a genuine scheduling conflict or a deliberate short-notice pressure test — the kind of meeting where the person with the least preparation time is the one most likely to reveal something they didn't intend to. Leah opened her working files. Three memos, forty-one pages. She knew every word, every number, every citation. She was prepared. But she was not prepared for what she found when she arrived at Conference Room 34-B. The room was smaller than she expected — eight chairs around a rectangular table, a wall-mounted screen for video calls, a window overlooking Lexington Avenue. David Choi was already seated, his laptop open, his face set in the neutral expression of a man who was about to deliver bad news to someone more powerful than himself. Beside David sat Howard Pemberton. Leah stopped in the doorway for half a second — no more, but enough. Pemberton was not supposed to be here. This was a clinical data meeting, not a legal strategy session. Pemberton's presence meant one of two things: either he was here to observe, or he was here to participate. If he was here to observe, he was watching her. If he was here to participate, he was testing her. Either way, she was being evaluated. "Ms. Marsh." Pemberton's voice was warm, avuncular — the voice of a man who had been charming people for forty years and had never once meant it. "Please, sit. I understand you've done excellent work on the NexGen analysis." "Thank you, Mr. Pemberton." Leah sat down, placing her files on the table in front of her. "I submitted the complete analysis to David on Thursday evening." "I've read it." Pemberton's eyes were on her face — not her hands this time, but her face, reading her expression the way a doctor reads a chart. "Thorough. Precise. Your identification of the five clinical data discrepancies is compelling. David tells me you cross-referenced the NexGen investor disclosures against the raw Phase III trial data." "I did." "And you found that all five discrepancies were upward adjustments." "Yes. Each discrepancy made the drug appear more effective than the raw data supported. Four of the five were within plausible statistical variance, but the fifth — the 3.7% overall response rate adjustment — is mathematically improbable given the patient sample size." Pemberton nodded slowly. "Mathematically improbable," he repeated. "An interesting phrase. Not 'impossible.' Not 'fraudulent.' 'Improbable.'" "I'm an analyst, Mr. Pemberton. I report what the data shows. The data shows a pattern of upward adjustment that falls outside normal variance. Whether that pattern reflects fraud, error, or coincidence is a question for the legal team and the SEC." "A careful answer." Pemberton smiled. It did not reach his eyes. "You're very careful, Ms. Marsh. David has remarked on it. So has Priya. You're careful with documents, careful with numbers, careful with your words." The room was very quiet. David was looking at his laptop, deliberately not looking at either of them. Leah could feel the pressure building — Pemberton was circling her, not physically, but conversationally, testing the perimeter of her composure. "I was raised to be careful," Leah said. "Were you?" Pemberton leaned back in his chair. "Tell me — where did you grow up?" The question was casual. Too casual. The kind of question that could be a genuine attempt at conversation or a calibrated probe, depending on what the questioner already knew. "Virginia," Leah said. "A small town outside Charlottesville. My father was a high school history teacher. My mother was a librarian." "Charming." Pemberton's smile widened by a fraction. "And your education?" "University of Virginia. Economics. Then a master's in public policy at Georgetown." "Impressive credentials for a junior analyst." Pemberton's eyes held hers. "Most junior analysts at Thorne Group come from Wharton, or Harvard Business School, or Stanford. Georgetown is — unusual." "Georgetown has an excellent public policy program." "It does. I'm not questioning the quality of your education, Ms. Marsh. I'm curious about the path that led you here. A small-town girl from Virginia, a public policy degree, and now you're doing clinical data analysis for a Fortune 500 company. That's an interesting trajectory." The video screen flickered. Sebastian Costa's face appeared — sharp-featured, dark-eyed, with the particular intensity of a man who was used to being the most powerful person in any room. He was sitting in what appeared to be his office at Costa Holdings, a glass-walled corner suite with a view of the Hudson River. "Good morning," Sebastian said. His voice was clipped, professional, but Leah could hear the strain underneath it — the strain of a man whose acquisition was under SEC scrutiny and whose shell company financing was about to be exposed. "David. Howard. Ms. Marsh." "Sebastian." Pemberton's tone shifted — warmer, more collegial, the tone of a man speaking to a client rather than a subordinate. "Thank you for joining us. We're reviewing the NexGen clinical data analysis before the SEC response team files its preliminary findings." "Let's get to it." Sebastian's eyes found Leah on the screen. He studied her for a moment — not the searching evaluation of Pemberton, but something more personal. More dangerous. "Ms. Marsh. David tells me you identified the discrepancies independently." "I did." "Independently." Sebastian leaned forward. "Meaning no one directed your attention to the NexGen data. You found the pattern on your own." "Correct." "Interesting." Sebastian's eyes narrowed. "Because the NexGen data has been reviewed by three separate teams over the past eighteen months — internal audit, external compliance, and the SEC's preliminary inquiry — and none of them flagged the 3.7% discrepancy. You found it in three weeks." Leah felt the temperature in the room drop by several degrees. This was not a meeting about clinical data. This was an interrogation. Sebastian was not interested in the numbers. He was interested in her. "The previous reviews focused on aggregate trial outcomes," Leah said. "My analysis cross-referenced investor disclosures against raw patient-level data. It's a different methodology. It produces different results." "A different methodology." Sebastian repeated the phrase like he was tasting it. "Where did you learn that methodology?" "It's a standard forensic accounting technique. Cross-referencing public disclosures against source data to identify discrepancies." "It's not standard in pharmaceutical analysis," Sebastian said. "It's standard in fraud investigation." The silence that followed was absolute. David still would not look up from his laptop. Pemberton's expression was unreadable — the neutral mask of a man who had spent his career saying nothing and making it sound like everything. "The SEC has requested a formal response by Friday," Pemberton said, breaking the silence. "David, I assume the team is on track?" David looked up. "We are. The preliminary findings will be filed by Wednesday. The full response by Friday." "Good. Ms. Marsh, your analysis will be included in the full response, with attribution. Is there anything else you'd like to add before we conclude?" Leah considered her options. She could deflect, apologize, downplay her findings. She could let Sebastian's accusation hang in the air unanswered, which would be the safe thing to do. Or she could do the thing that Catherine Marsh — the character she had created — would never do, but that Leah Chen — the woman she actually was — had been training for since the night she died. "I'd like to add one thing," Leah said. "The NexGen data discrepancies are not isolated. I've identified similar patterns in at least four other Thorne Foundation-funded clinical trials — Veritas Labs, plus three additional studies conducted between 2000 and 2018. The same directional adjustment. The same below-threshold methodology. The same absence of documentation explaining the variance. If the SEC is investigating NexGen, they should be aware that the pattern is systemic, not anomalous." The room went very still. Pemberton's expression did not change. Not a flicker. Not a twitch. Forty years of courtroom poker face, holding steady under pressure that would have broken a lesser man. But his right hand — resting on the table beside his coffee cup — moved. A small movement, barely visible. His index finger tapped the table once. A single tap. Then it was still. Sebastian's face, on the screen, had gone very white. "Systemic," Sebastian said. "You're saying this is systemic." "I'm saying the pattern exists across multiple trials, multiple years, and multiple principal investigators. Whether it's systemic is a question for investigators, not analysts." Sebastian opened his mouth to speak, then closed it. He looked at Pemberton — a quick, sharp glance that contained a question Leah could read even through a video screen: Did you know about this? Pemberton did not answer the question. He did not need to. His face said everything. "Thank you, Ms. Marsh," Pemberton said. "That will be all." Leah gathered her files and stood. She walked to the door without looking back. But as she reached the threshold, Pemberton spoke again. "Ms. Marsh." She stopped. Did not turn around. "I've been practicing law for forty-two years," Pemberton said. "In that time, I've learned that the most dangerous people in any organization are not the ones who make mistakes. They're the ones who find them." Leah paused. The weight of the words settled over her like a cloak. "Good day, Mr. Pemberton," she said. And left. She took the elevator to the lobby, walked out through the revolving doors, and turned north on Lexington Avenue. The May morning was cool and bright, the sidewalks crowded with the Monday energy of people going to work, buying coffee, checking phones, living their ordinary lives. Leah walked four blocks before her hands stopped shaking. She had just expanded the scope of the SEC investigation from a single drug trial to a twenty-year pattern of clinical data manipulation spanning multiple Foundation-funded studies. She had done it in front of Howard Pemberton, the architect of the cover-up, and Sebastian Costa, the man whose acquisition depended on the cover-up remaining intact. It was the most dangerous thing she had done since walking into the Thorne Group building as Catherine Marsh. And it was exactly what she had needed to do. Pemberton knew. He had known the moment she mentioned the systemic pattern that Catherine Marsh was not who she claimed to be. No junior analyst with a Georgetown public policy degree would have identified a twenty-year fraud pattern in three weeks. No careful, ordinary woman from Virginia would have sat in that conference room and expanded an SEC investigation with a single paragraph. Pemberton knew. And now he had to decide what to do about it. Leah pulled out her phone and sent Ethan a text: "Meeting with Pemberton and Sebastian. I expanded the SEC scope. Four additional trials. Pemberton's finger tapped the table once when I said 'systemic.' He knows. Watch your back." The response came in twelve seconds: "How bad?" "Bad. But not unexpected. We're past the point of careful. Time to accelerate." Ethan's response was a single word: "Agreed." Leah put her phone away and kept walking. She did not go back to her apartment. She did not go to Thorne Group. She walked to a coffee shop on Third Avenue, ordered a black coffee, sat in the corner, and opened her laptop. She had a statement to write. Not for the SEC, not for the press, not for the lawyers. For Catherine Thorne. A written testimony, signed and notarized, detailing everything Catherine had told her yesterday afternoon. The net was tightening. On all of them. But Leah had spent two years learning how to move inside a net. She knew the gaps. She knew the weak points. She knew where the threads could be cut. And she knew that the person holding the scissors was her.